Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.…
Nektar (NKTR) Q3 2026 Earnings Call Transcript
Nektar Therapeutics (NASDAQ: NKTR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 63 employees.
The shares were at 30.20 USD on 20 November 2026, down 47.9% over 52 weeks. Its 52-week range is 30.13 USD to 109.00 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.03B USD.
Nektar Therapeutics reports return on equity of -182.6%, an operating margin of -303.6% and revenue down 20.4% year over year.
It holds more cash than debt, a net cash position of 485.69M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.